An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|18|29|4475-4484

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.29, 2012-10, pp. : 4475-4484

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-&bgr;-1b treatment in relapsing remitting MS

By Goertsches Robert H Hecker Michael Koczan Dirk Serrano-Fernandez Pablo Moeller Steffen Thiesen Hans-Juergen Zettl Uwe K

Pharmacogenomics, Vol. 11, Iss. 2, 2010-02 ,pp. : 147-161

Future Medicine

Access to resources Recommend Favorite

Treatment of even mild to moderate Crohn's disease is a long-term challenge due to its remitting and relapsing course

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 25, Iss. 6, 2009-06 ,pp. : 10-12

Adis International

Access to resources Recommend Favorite

IFN- treatment cost driver in relapsing-remitting MS

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 458, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

IFN- treatment cost driver in relapsing-remitting MS

Inpharma, Vol. 1, Iss. 1448, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite